» Articles » PMID: 11734618

P2X Receptors and Nociception

Overview
Journal Pharmacol Rev
Specialty Pharmacology
Date 2001 Dec 6
PMID 11734618
Citations 111
Authors
Affiliations
Soon will be listed here.
Abstract

The potential importance for nociception of P2X receptors, the ionotropic receptors activated by ATP, is underscored by the variety of pain states in which this endogenous ligand can be released. Several important findings have been made recently indicating that P2X receptors can be involved in pain mechanisms both centrally and in the periphery. The roles of ATP at these two sites and the P2X receptor subtypes involved appear to be different. In the periphery, ATP can be released as a result of tissue injury, visceral distension, or sympathetic activation and can excite nociceptive primary afferents by acting at homomeric P2X(3) or heteromeric P2X(2/3) receptors. Centrally, ATP released from central afferent terminals or second order neurons can modulate neurotransmitter release or postsynaptically activate neurons involved in central nociceptive transmission, with P2X(2), P2X(4), P2X(6), and some other receptors being potentially involved. Evidence from in vivo studies suggests that peripheral ATPergic mechanisms are most important under conditions of acute tissue injury and inflammation whereas the relevance of central mechanisms appears to be more limited. Furthermore, the release of ATP and P2X receptor-mediated afferent activation appear to have been implicated in visceral and neuropathic pain; the importance of the ATPergic component in these states needs to be investigated further. Thus, peripheral P2X receptors, and homomeric P2X(3) and/or heteromeric P2X(2/3) receptors in particular, constitute attractive targets for analgesic drugs. The development of selective antagonists of these receptors, suitable for a systemic in vivo use although apparently difficult, may prove a useful strategy to generate analgesics with a novel mechanism of action.

Citing Articles

Neuroimmune recognition of allergens.

Chiu I, Sokol C Curr Opin Immunol. 2024; 90:102458.

PMID: 39213825 PMC: 11423315. DOI: 10.1016/j.coi.2024.102458.


Quercetin Ameliorates Neuropathic Pain after Brachial Plexus Avulsion Suppressing Oxidative Damage through Inhibition of PKC/MAPK/ NOX Pathway.

Huang Y, Zhang X, Zou Y, Yuan Q, Xian Y, Lin Z Curr Neuropharmacol. 2023; 21(11):2343-2361.

PMID: 37533160 PMC: 10556381. DOI: 10.2174/1570159X21666230802144940.


Resensitization of TRPV1 channels after the P2 receptor activation in sensory neurons of spinal ganglia in rats.

Petrushenko O, Stratiievska A, Petrushenko M, Lukyanetz E Front Cell Neurosci. 2023; 17:1192780.

PMID: 37323583 PMC: 10267357. DOI: 10.3389/fncel.2023.1192780.


Neuroimmune Mechanisms Underlying Post-acute Sequelae of SARS-CoV-2 (PASC) Pain, Predictions from a Ligand-Receptor Interactome.

Lesnak J, Mazhar K, Price T Curr Rheumatol Rep. 2023; 25(9):169-181.

PMID: 37300737 PMC: 10256978. DOI: 10.1007/s11926-023-01107-8.


P2-type purinergic signaling in the regulation of pancreatic β-cell functional plasticity as a promising novel therapeutic approach for the treatment of type 2 diabetes?.

Mesto N, Movassat J, Tourrel-Cuzin C Front Endocrinol (Lausanne). 2023; 13:1099152.

PMID: 37065173 PMC: 10099247. DOI: 10.3389/fendo.2022.1099152.